Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5585

1.

[A New Twist on the Administration of Naldemedine for Opioid-Induced Constipation in an Outpatient].

Shikada Y, Emi Y, Kometani T, Ochiai T, Fujii M, Noda Y, Kajiwara M, Ikeda M, Asonuma S, Mori M.

Gan To Kagaku Ryoho. 2018 Jul;45(7):1075-1079. Japanese.

PMID:
30042276
2.

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report.

Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D.

Int J Pharm Compd. 2018 Jul-Aug;22(4):270-278.

PMID:
30021181
3.

Methylnaltrexone bromide for the treatment of opioid-induced constipation.

Mozaffari S, Nikfar S, Abdollahi M.

Expert Opin Pharmacother. 2018 Jul;19(10):1127-1135. doi: 10.1080/14656566.2018.1491549. Epub 2018 Jul 6. Review.

PMID:
29979903
4.

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.

Cote B, Ross B, Fortner J, Rao D.

Int J Pharm Compd. 2018 May-Jun;22(3):252-256.

PMID:
29878893
5.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.

Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3. Review.

PMID:
29869799
6.

Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection.

Azizi H, Mirzaeei H, Nasiri AA, Bazi A, Mirzapour A, Khatami M, Nahavandi KH, Azimi A, Yaghoobi H.

Exp Parasitol. 2018 Jun;189:66-71. doi: 10.1016/j.exppara.2018.04.015. Epub 2018 Apr 27.

PMID:
29729492
7.

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.

Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA.

Drug Alcohol Depend. 2018 Jun 1;187:171-178. doi: 10.1016/j.drugalcdep.2018.02.023. Epub 2018 Apr 10.

8.

Cirrhosis induced by bile duct ligation alleviates acetic acid intestinal damages in rats: Involvements of nitrergic and opioidergic systems.

Rahimi N, Hassanipour M, Allahabadi NS, Sabbaghziarani F, Yazdanparast M, Dehpour A.

Pharmacol Rep. 2018 Jun;70(3):426-433. doi: 10.1016/j.pharep.2017.11.010. Epub 2017 Nov 22.

PMID:
29626646
9.

Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.

Ragguett RM, Rong C, Rosenblat JD, Ho RC, McIntyre RS.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):475-482. doi: 10.1080/17425255.2018.1459564. Epub 2018 Apr 6. Review.

PMID:
29621905
10.

Low dose naltrexone for induction of remission in Crohn's disease.

Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N.

Cochrane Database Syst Rev. 2018 Apr 1;4:CD010410. doi: 10.1002/14651858.CD010410.pub3. Review.

PMID:
29607497
11.

SNC80 and naltrindole modulate voltage-dependent sodium, potassium and calcium channels via a putatively delta opioid receptor-independent mechanism.

Moravčíková L, Královičová J, Lacinová Ľ.

Gen Physiol Biophys. 2018 May;37(3):299-307. doi: 10.4149/gpb_2018009. Epub 2018 Mar 28.

PMID:
29589835
12.

Salvinorin A preserves cerebral pial artery autoregulation after forebrain ischemia via the PI3K/AKT/cGMP pathway.

Dong HP, Zhou W, Ma XX, He ZZ, Wang ZH.

Braz J Med Biol Res. 2018 Mar 15;51(5):e6714. doi: 10.1590/1414-431X20176714.

13.

Neurokinin B receptor agonist and Dynorphin receptor antagonist stimulated luteinizing hormone secretion in fasted male rodents.

Matsuzaki T, Tungalagsuvd A, Munkhzaya M, Iwasa T, Yano K, Mayila Y, Tokui T, Yanagihara R, Matsui S, Kato T, Kuwahara A, Irahara M.

Endocr J. 2018 Apr 26;65(4):485-492. doi: 10.1507/endocrj.EJ17-0136. Epub 2018 Feb 23.

14.

Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids.

Haddadi NS, Foroutan A, Shakiba S, Afshari K, Ostadhadi S, Daneshpazhooh M, Dehpour AR.

Arch Dermatol Res. 2018 Mar;310(2):165-172. doi: 10.1007/s00403-018-1809-9. Epub 2018 Jan 19.

PMID:
29352328
15.

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.

Weinstock LB, Brook JB, Myers TL, Goodman B.

BMJ Case Rep. 2018 Jan 11;2018. pii: bcr-2017-221405. doi: 10.1136/bcr-2017-221405.

16.

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.

J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421.

PMID:
29308591
17.

The effects of recurrent hypoglycaemia and opioid antagonists on the adrenal catecholamine synthetic capacity in a rat model of HAAF.

Senthilkumaran M, Bobrovskaya L.

Auton Neurosci. 2018 Mar;210:76-80. doi: 10.1016/j.autneu.2017.12.004. Epub 2017 Dec 16.

PMID:
29290404
18.

Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor.

Wu Q, Chen X, Wang J, Sun P, Weng M, Chen W, Sun Z, Zhu M, Miao C.

Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):156-163. doi: 10.1093/abbs/gmx131.

PMID:
29267844
19.

Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts.

Salimi V, Mirzaei H, Ramezani A, Tahamtan A, Jamali A, Shahabi S, Golaram M, Minaei B, Gharagozlou MJ, Mahmoodi M, Bont L, Shokri F, Mokhtari-Azad T.

Med Microbiol Immunol. 2018 Apr;207(2):105-115. doi: 10.1007/s00430-017-0531-0. Epub 2017 Dec 18. Erratum in: Med Microbiol Immunol. 2018 Nov;207(5-6):345.

PMID:
29256094
20.

Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.

Kelly MM, Reilly E, Quiñones T, Desai N, Rosenheck R.

Drug Alcohol Depend. 2018 Feb 1;183:111-117. doi: 10.1016/j.drugalcdep.2017.10.017. Epub 2017 Dec 2.

PMID:
29245103

Supplemental Content

Loading ...
Support Center